Claims for Patent: 6,864,264

Summary for Patent: 6,864,264

Title:	1-adamantyl chalcones for the treatment of proliferative disorders
Abstract:	The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I], ##STR1## wherein the substituents are as defined in the specification.
Inventor(s):	Anderson; Gloria L. (Atlanta, GA), Kaimari; Tawfeq Abdul-Raheem (Kennesaw, GA)
Assignee:
Application Number:	10/224,723
Patent Claims:	1. A compound of the formula: ##STR29## wherein. R.sub.1 is Ad- or Ad-(L1)n-, wherein n is 0 or 1, Ad is adamantyl, and L1 is C1-6 alkalene; R.sub.2 is HET; HET is substituted or unsubstituted quinolyl wherein the substituent is X; wherein X is selected from the group consistng of hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 akyl amino, C1-6 dialkyl amino, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano and a phosphorus containing group; Y is H, or C1-6 alkyl; or a phamaeuically acceptable salt or derivative thereof. 2. A compound according to claim 1, having the formula ##STR30## wherein HET is methyl-substituted or unsubsutituted quinolyl; or a pharmaceutically acceptable salt or derivative thereof. 3. A compound according to claim 1, having the formula ##STR31## wherein HET is selected from the group consisting of quinolin-2-yl, quinolin-3-yl, and quinolin-4-yl, or a pharmaceutically acceptable salt or derivative thereof. 4. A pharmaceutical composition comprising an effective amount of a compound of claim 1 having the formula ##STR32## wherein: R.sub.1 is Ad- or Ad-(L1)n-, wherein n is 0 or 1, Ad is adamantyl, and L1 is C1-6 alkylene; R.sub.2 is HET; HET is substituted or unsubstituted quinolyl, wherein the substituent is X; wherein X is selected from the group consisting of hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano and a phosphorus containing group; Y is H, or C1-6 alkyl; or a pharmaceutically acceptable salt or derivative thereof, in combination with a pharmaceutically acceptable carrier. 5. A pharmaceutical composition comprising an effective amount of a compound of claim 1 having the formula ##STR33## wherein HET is selected from the group consisting of quinolin-2-yl, quinolin-3-yl, and quinolin-4-yl; or a pharmaceutically acceptable salt or derivative thereof in combination with a pharmaceutically acceptable carrier. 6. A pharmaceutical composition comprising an effective amount of a compound of claim 1 having the formula ##STR34## wherein HET is methyl-substituted or unsubstituted quinolyl; or a pharmaceutically acceptable salt or derivative thereof. 7. A method for the treatment of breast cancer comprising administering to a host in need of such treatment an effective amount of a compound of claim 1 having the formula ##STR35## wherein Ad is adamantyl, HET is selected from the group consisting of pyrid-2-yl, pyrid-2-yl, pyrid-2-yl, 6-methylpyrid-2-yl, quinolin-2-yl, quinolin-3-yl, and quinolin-4-yl, or a pharmaceutically acceptable salt or derivative thereof, optionally in combination with a pharmaceutically acceptable carrier. 8. A method for the treatment of breast cancer comprising administering to a host in need of such treatment an effective amount of a compound having the formula ##STR36## wherein: R.sub.1 is Ad- or Ad-(L1)n-, wherein n is 0 or 1, Ad is adamantyl, and L1 is a linking group selected from the group consisting of C1-6 alkylene; R.sub.2 is HET; HET is selected from the group consisting of substituted or unsubstituted pyridinyl, and quinolyl, wherein the substituent is X; wherein X is selected from the group consisting of hydrogen, straight chain or branched C1-6 alkyl, halo, amino, C1-6 alkyl amino, C1-6 dialkyl amino, C1-6 alkoxy, C1-6 aralkoxyl, aryl, C1-6 aralkyl, nitro, cyano and a phosphorus containing group; Y is H, or C1-6 alkyl; or a pharmaceutically acceptable salt or derivative thereof, optionally in combination with a pharmaceutically acceptable carrier. 9. The method according to claim 8, wherein the compound is administered in combination with at least one other chemotherapeutic agent selected from the group consisting of tamoxifen, toremifene, idoxifene, droloxifene, TAT-59, LY117018, raloxifene, genistein, doxyrubicin, Taxol, Taxotere, aredia, arimidex, navilbine, busulfan, cisplatin, cyclophosphamide (Cytoxan), dacarbazine, ifosfamide, mechlorethamine (Mustargen), melphalan, carmustine, lomustine, 5-fluorouracil, methotrexate, gemcitabine, cytarabine (Ara-C), fludarabine, bleomycin, dactinomycin, daunorubicin, idarubicin, paclitaxel, docetaxel, etoposide, vinblastine, vincristine, vinorelbine, prednisone, dexamethasone, and herceptin, optionally in combination with a pharmaceutically acceptable carrier. 10. The method according to claim 8 comprising administering to a host an effective amount of a compound having the formula ##STR37## wherein HET is methyl-substituted or unsubstituted quinolyl; or a pharmaceutically acceptable salt or derivative thereof. 11. The method according to claim 8 comprising administering to a host an effective amount of a compound having the formula ##STR38## wherein HET is methyl-substituted or unsubstituted quinolyl; or a pharmaceutically acceptable salt or derivative thereof, wherein the compound is administered in combination with at least one other chemotherapeutic agent selected from the group consisting of tamoxifen, toremifene, idoxifene, droloxifene, TAT-59, LY117018, raloxifene, genistein, doxyrubicin, Taxol, Taxotere, aredia, arimidex, navilbine, busulfan, cisplatin, cyclophosphamide (Cytoxan), dacarbazine, ifosfamide, mechlorethamine (Mustargen), melphalan, carumstine, lomustine, 5-fluorouracil, methotrexate, gemcitabine, cytarabine (Ara-C), fludarabine, bleomycin, dactinomycin, daunorubicin, idarubicin, paclitaxel, docetaxel, etoposide, vinblastine, vincristine, vinorelbine, prednisone, dexamethasone, and herceptin, optionally in combination with a pharmaceutically acceptable carrier. 12. The method according to claim 8 comprising administering to a host an effective amount of a compound having the formula ##STR39## wherein HET is selected from the group consisting of quinolin-2-yl, quinolin-3-yl, and quinolin-4-yl, or a pharmaceutically acceptable salt or derivative thereof, wherein the compound is administered in combination with at least one other chemotherapeutic agent selected from the group consisting of tamoxifen, toremifene, idoxifene, droloxifene, TAT-59, LY117018, raloxifene, genistein, doxyrubicin, Taxol, Taxotere, aredia, arimidex, navilbine, busulfan, cisplatin cyclophosphamide (Cytoxan), dacarbazine, ifosfamide, mechlorethamine (Mustargen), melphalan, carmustine, lomustine, 5-fluorouracil, methotrexate, gemcitabine, cytarabine (Ara-C), fludarabine, bleomycin, dactinomycin, daunorubicin, idarubicin, paclitaxel, docetaxel, etoposide, vinblastine, vincristine, vinorelbine, prednisone, dexamethasone, and herceptin, optionally in combination with a pharmaceutically acceptable carrier.

Details for Patent 6,864,264

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-03-29